Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time?

Pailler E, Faugeroux V, Oulhen M, Catelain C, Farace F.

Transl Lung Cancer Res. 2017 Aug;6(4):444-453. doi: 10.21037/tlcr.2017.07.01. Review.

2.

Filter-Adapted Fluorescent In Situ Hybridization (FA-FISH) for Filtration-Enriched Circulating Tumor Cells.

Oulhen M, Pailler E, Faugeroux V, Farace F.

Methods Mol Biol. 2017;1634:133-141. doi: 10.1007/978-1-4939-7144-2_10.

PMID:
28819846
3.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC.

Eur J Cancer. 2017 Sep;83:185-193. doi: 10.1016/j.ejca.2017.05.016. Epub 2017 Jul 22.

PMID:
28743036
4.

A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.

Lindsay CR, Faugeroux V, Michiels S, Pailler E, Facchinetti F, Ou D, Bluthgen MV, Pannet C, Ngo-Camus M, Bescher G, Caramella C, Billiot F, Remon J, Planchard D, Soria JC, Besse B, Farace F.

Ann Oncol. 2017 Jul 1;28(7):1523-1531. doi: 10.1093/annonc/mdx156.

PMID:
28633480
5.

Detection of Gene Rearrangements in Circulating Tumor Cells: Examples of ALK-, ROS1-, RET-Rearrangements in Non-Small-Cell Lung Cancer and ERG-Rearrangements in Prostate Cancer.

Catelain C, Pailler E, Oulhen M, Faugeroux V, Pommier AL, Farace F.

Adv Exp Med Biol. 2017;994:169-179. doi: 10.1007/978-3-319-55947-6_9. Review.

PMID:
28560674
6.

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.

Pailler E, Oulhen M, Borget I, Remon J, Ross K, Auger N, Billiot F, Ngo Camus M, Commo F, Lindsay CR, Planchard D, Soria JC, Besse B, Farace F.

Cancer Res. 2017 May 1;77(9):2222-2230. doi: 10.1158/0008-5472.CAN-16-3072.

PMID:
28461563
7.

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Vielh P, Farace F, Valleix F, Podoll T, Kuramochi Y, Miyashita I, Hosono O, Dang NH, Ohnuma K, Yamada T, Kaneko Y, Morimoto C.

Br J Cancer. 2017 Apr 25;116(9):1126-1134. doi: 10.1038/bjc.2017.62. Epub 2017 Mar 14.

8.

Method for semi-automated microscopy of filtration-enriched circulating tumor cells.

Pailler E, Oulhen M, Billiot F, Galland A, Auger N, Faugeroux V, Laplace-Builhé C, Besse B, Loriot Y, Ngo-Camus M, Hemanda M, Lindsay CR, Soria JC, Vielh P, Farace F.

BMC Cancer. 2016 Jul 14;16:477. doi: 10.1186/s12885-016-2461-4.

9.

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.

Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L.

Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. Epub 2016 Jul 11.

10.

Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.

Massard C, Oulhen M, Le Moulec S, Auger N, Foulon S, Abou-Lovergne A, Billiot F, Valent A, Marty V, Loriot Y, Fizazi K, Vielh P, Farace F.

Oncotarget. 2016 Aug 23;7(34):55069-55082. doi: 10.18632/oncotarget.10396.

11.

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.

Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, Fizazi K, Massard C, Farace F.

BMC Cancer. 2016 Feb 29;16:168. doi: 10.1186/s12885-016-2192-6.

12.

The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer.

Ross K, Pailler E, Faugeroux V, Taylor M, Oulhen M, Auger N, Planchard D, Soria JC, Lindsay CR, Besse B, Vielh P, Farace F.

Expert Rev Mol Diagn. 2015;15(12):1605-29. doi: 10.1586/14737159.2015.1111139. Epub 2015 Nov 13. Review.

PMID:
26564313
13.

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.

Bahleda R, Hollebecque A, Varga A, Gazzah A, Massard C, Deutsch E, Amellal N, Farace F, Ould-Kaci M, Roux F, Marzin K, Soria JC.

Br J Cancer. 2015 Nov 17;113(10):1413-20. doi: 10.1038/bjc.2015.374. Epub 2015 Oct 29.

14.

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.

Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, Perri P, Tchirkov A, Matta J, Lapierre V, Shekarian T, Valsesia-Wittmann S, Commo F, Prada N, Poirier-Colame V, Bressac B, Cotteret S, Brugieres L, Farace F, Chaput N, Kroemer G, Valteau-Couanet D, Zitvogel L.

Sci Transl Med. 2015 Apr 15;7(283):283ra55. doi: 10.1126/scitranslmed.aaa2327.

PMID:
25877893
15.

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.

Pailler E, Auger N, Lindsay CR, Vielh P, Islas-Morris-Hernandez A, Borget I, Ngo-Camus M, Planchard D, Soria JC, Besse B, Farace F.

Ann Oncol. 2015 Jul;26(7):1408-15. doi: 10.1093/annonc/mdv165. Epub 2015 Apr 6.

16.

High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection.

Autebert J, Coudert B, Champ J, Saias L, Guneri ET, Lebofsky R, Bidard FC, Pierga JY, Farace F, Descroix S, Malaquin L, Viovy JL.

Lab Chip. 2015 May 7;15(9):2090-101. doi: 10.1039/c5lc00104h.

PMID:
25815443
17.

Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.

Raphael J, Massard C, Gong IY, Farace F, Margery J, Billiot F, Hollebecque A, Besse B, Soria JC, Planchard D.

Cancer Biomark. 2015;15(2):151-6. doi: 10.3233/CBM-140448.

PMID:
25519011
18.

Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.

Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, Rougier P, Ducreux M.

Eur J Cancer. 2014 Dec;50(18):3107-15. doi: 10.1016/j.ejca.2014.10.001. Epub 2014 Oct 18.

PMID:
25454413
19.

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer.

Faugeroux V, Pailler E, Auger N, Taylor M, Farace F.

Front Oncol. 2014 Nov 5;4:281. doi: 10.3389/fonc.2014.00281. eCollection 2014. Review.

20.

A simple and cheap system to speed up and to control the tumescent technique procedure: the Tedde's system.

Rubino C, Marongiu F, Manzo MJ, Tedde G, Madonia M, Campus GV, Farace F.

Eur Rev Med Pharmacol Sci. 2014 Jun;18(11):1647-8.

21.

Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.

Le Moulec S, Hadoux J, Gontier E, Chargari C, Helissey C, Lamand V, Tanz R, Farace F, Vedrine L, Bonardel G, Soria JC, Besse B.

Bull Cancer. 2013 Dec;100(12):30-7. doi: 10.1684/bdc.2013.1864.

PMID:
24316967
22.

Negative pressure wound therapy and external fixation device: a simple way to seal the dressing.

Bulla A, Farace F, Uzel AP, Casoli V.

J Orthop Trauma. 2014 Jul;28(7):e176-7. doi: 10.1097/BOT.0000000000000013.

PMID:
24296597
23.

A scanning electron microscope study and statistical analysis of adipocyte morphology in lipofilling: comparing the effects of harvesting and purification procedures with 2 different techniques.

Rubino C, Mazzarello V, Faenza M, Montella A, Santanelli F, Farace F.

Ann Plast Surg. 2015 Jun;74(6):718-21. doi: 10.1097/SAP.0b013e3182a1e5a4.

PMID:
24149403
24.

Reply: An original technique for securing the inflation port in Becker implant-based breast reconstruction.

Farace F, Bulla A, Marongiu F, Faenza M, Campus GV.

Plast Reconstr Surg. 2013 Sep;132(3):466e. doi: 10.1097/PRS.0b013e31829accdf. No abstract available.

PMID:
23985661
25.

Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.

Sessa C, Lorusso P, Tolcher A, Farace F, Lassau N, Delmonte A, Braghetti A, Bahleda R, Cohen P, Hospitel M, Veyrat-Follet C, Soria JC.

Clin Cancer Res. 2013 Sep 1;19(17):4832-42. doi: 10.1158/1078-0432.CCR-13-0427. Epub 2013 Jul 5.

26.

A new contrast agent for radiological and dissection studies of the arterial network of anatomic specimens.

Bulla A, Casoli C, Farace F, Mazzarello V, De Luca L, Rubino C, Montella A.

Surg Radiol Anat. 2014 Jan;36(1):79-83. doi: 10.1007/s00276-013-1143-z. Epub 2013 Jun 4.

PMID:
23732392
27.

Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.

Pailler E, Adam J, Barthélémy A, Oulhen M, Auger N, Valent A, Borget I, Planchard D, Taylor M, André F, Soria JC, Vielh P, Besse B, Farace F.

J Clin Oncol. 2013 Jun 20;31(18):2273-81. doi: 10.1200/JCO.2012.44.5932. Epub 2013 May 13.

PMID:
23669222
28.

Anaplastic large cell lymphoma of the breast arising around mammary implant capsule: an Italian report.

Farace F, Bulla A, Marongiu F, Campus GV, Tanda F, Lissia A, Cossu A, Fozza C, Rubino C.

Aesthetic Plast Surg. 2013 Jun;37(3):567-71. doi: 10.1007/s00266-013-0120-6. Epub 2013 Apr 26.

PMID:
23620008
29.

Is mammary reconstruction with the anatomical Becker expander a simple procedure? Complications and hidden problems leading to secondary surgical procedures: a follow-up study.

Farace F, Faenza M, Bulla A, Rubino C, Campus GV.

J Plast Reconstr Aesthet Surg. 2013 Jun;66(6):741-6. doi: 10.1016/j.bjps.2013.02.004. Epub 2013 Mar 9.

PMID:
23478009
30.

The ocular stick as wound dressing in lower-eyelid reconstruction.

Farace F, Faenza M, Bulla A, Marongiu F, Rubino C, Campus GV.

Aesthetic Plast Surg. 2013 Apr;37(2):480-1. doi: 10.1007/s00266-013-0060-1. Epub 2013 Jan 30. No abstract available.

PMID:
23361956
31.

A case series study on complications after breast augmentation with Macrolane™.

Becchere MP, Farace F, Dessena L, Marongiu F, Bulla A, Simbula L, Meloni GB, Rubino C.

Aesthetic Plast Surg. 2013 Apr;37(2):332-5. doi: 10.1007/s00266-012-9971-5. Epub 2013 Jan 24.

PMID:
23344467
32.

A multivariate analysis of factors influencing the drain permanence in breast reconstruction with Becker implant.

Rubino C, Campus GV, Bulla A, Muzzeddu GP, Fara G, Farace F.

J Plast Reconstr Aesthet Surg. 2013 Mar;66(3):e84-6. doi: 10.1016/j.bjps.2012.11.017. Epub 2012 Dec 4. No abstract available.

PMID:
23218654
33.

Circulating tumor cells in lung cancer.

Young R, Pailler E, Billiot F, Drusch F, Barthelemy A, Oulhen M, Besse B, Soria JC, Farace F, Vielh P.

Acta Cytol. 2012;56(6):655-60. doi: 10.1159/000345182. Epub 2012 Nov 24. Review.

PMID:
23207444
34.

Compartment syndrome at the fibula flap's donor site and salvage by anerolateral thigh chimeric flap.

Rubino C, Faenza M, Muzzeddu GP, Massarelli O, Tullio A, Farace F.

Microsurgery. 2012 Nov;32(8):657-8. doi: 10.1002/micr.22032. Epub 2012 Jul 23. No abstract available.

PMID:
22821839
35.

Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma.

Boige V, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, Pignon JP, Vimond N, Bouvet-Forteau N, De Baere T, Ducreux M, Farace F.

Oncologist. 2012;17(8):1063-72. doi: 10.1634/theoncologist.2011-0465. Epub 2012 Jun 15.

36.

Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.

Taylor M, Billiot F, Marty V, Rouffiac V, Cohen P, Tournay E, Opolon P, Louache F, Vassal G, Laplace-Builhé C, Vielh P, Soria JC, Farace F.

Cancer Discov. 2012 May;2(5):434-49. doi: 10.1158/2159-8290.CD-11-0171. Epub 2012 Mar 30.

37.

The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy.

Arnedos M, André F, Farace F, Lacroix L, Besse B, Robert C, Soria JC, Eggermont AM.

Mol Oncol. 2012 Apr;6(2):204-10. doi: 10.1016/j.molonc.2012.02.008. Epub 2012 Mar 16. Review.

38.

A superficial texture analysis of 70% glycolic acid topical therapy and striae distensae.

Mazzarello V, Farace F, Ena P, Fenu G, Mulas P, Piu L, Rubino C.

Plast Reconstr Surg. 2012 Mar;129(3):589e-590e. doi: 10.1097/PRS.0b013e3182419c40. No abstract available.

PMID:
22374035
39.

Prognostic value of circulating VEGFR2+ bone marrow-derived progenitor cells in patients with advanced cancer.

Massard C, Borget I, Le Deley MC, Taylor M, Gomez-Roca C, Soria JC, Farace F.

Eur J Cancer. 2012 Jun;48(9):1354-62. doi: 10.1016/j.ejca.2012.01.021. Epub 2012 Feb 25.

PMID:
22370181
40.

Filling-port complications in Becker expanders.

Farace F, Faenza M, Sanna M, Campus GV, Rubino C.

Plast Reconstr Surg. 2012 Feb;129(2):386e-387e. doi: 10.1097/PRS.0b013e31823aef0c. No abstract available.

PMID:
22286478
41.

Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study.

Bonvalot S, de Baere T, Mendiboure J, Paci A, Farace F, Drouard-Troalen L, Bonnet L, Hakime A, Bonniaud G, Raynard B, Israel P, Le Cesne A, Eggermont AM, Laplanche A, Muret J.

Ann Surg. 2012 Feb;255(2):281-6. doi: 10.1097/SLA.0b013e318242ebe7.

PMID:
22241290
42.

Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer.

Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F.

Br J Cancer. 2011 Oct 25;105(9):1338-41. doi: 10.1038/bjc.2011.405. Epub 2011 Oct 4.

43.

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.

Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D, Le Moulec S, André F, Fizazi K, Soria JC, Vielh P.

Br J Cancer. 2011 Sep 6;105(6):847-53. doi: 10.1038/bjc.2011.294. Epub 2011 Aug 9.

44.

Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.

Malka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, Pierga JY, Conroy T, Chauffert B, François E, Guichard P, Galais MP, Cvitkovic F, Ducreux M, Farace F.

Ann Oncol. 2012 Apr;23(4):919-27. doi: 10.1093/annonc/mdr365. Epub 2011 Aug 8.

PMID:
21825101
45.

Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.

Farace F, Gross-Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, Billiot F, Mauguen A, Hill C, Escudier B.

Br J Cancer. 2011 Mar 29;104(7):1144-50. doi: 10.1038/bjc.2011.72. Epub 2011 Mar 8.

46.

Optimizing the use of sentinel skin paddle in monitoring buried fasciocutaneous free flaps.

Rubino C, Farace F, Fara G, Dessena L, Faenza M.

Plast Reconstr Surg. 2011 Mar;127(3):62e-63e. doi: 10.1097/PRS.0b013e31820635a1. No abstract available.

PMID:
21364387
47.

External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study.

Kraan J, Sleijfer S, Strijbos MH, Ignatiadis M, Peeters D, Pierga JY, Farace F, Riethdorf S, Fehm T, Zorzino L, Tibbe AG, Maestro M, Gisbert-Criado R, Denton G, de Bono JS, Dive C, Foekens JA, Gratama JW.

Cytometry B Clin Cytom. 2011 Mar;80(2):112-8. doi: 10.1002/cyto.b.20573. Epub 2010 Nov 10.

48.

The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.

Rössler J, Monnet Y, Farace F, Opolon P, Daudigeos-Dubus E, Bourredjem A, Vassal G, Geoerger B.

Int J Cancer. 2011 Jun 1;128(11):2748-58. doi: 10.1002/ijc.25611. Epub 2010 Oct 8.

49.

Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays.

Saliba AE, Saias L, Psychari E, Minc N, Simon D, Bidard FC, Mathiot C, Pierga JY, Fraisier V, Salamero J, Saada V, Farace F, Vielh P, Malaquin L, Viovy JL.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14524-9. doi: 10.1073/pnas.1001515107. Epub 2010 Aug 2.

50.

The arrow flap for nipple reconstruction: long term results.

Farace F, Bulla A, Puddu A, Rubino C.

J Plast Reconstr Aesthet Surg. 2010 Oct;63(10):e756-7. doi: 10.1016/j.bjps.2010.05.038. Epub 2010 Jul 2. No abstract available.

PMID:
20580338

Supplemental Content

Loading ...
Support Center